Our investors

CellCentric is a biotechnology company focused on advancing CCS1477 for prostate and other cancers

CellCentric is a privately held, UK company with Morningside Venture Investments as its majority shareholder, who provided the latest $26m to take CCS1477 into the clinic for multiple indications.

Other earlier research funding came from Providence Investment Company, Takeda Ventures, UK Innovation Science & Seed Fund, Avlar, NESTA and the University of Cambridge.

CellCentric has also benefited from significant non-dilutive financial awards, including from UKRI/InnovateUK’s Biomedical Catalyst programme.